336
Participants
Start Date
March 24, 2021
Primary Completion Date
December 24, 2026
Study Completion Date
June 2, 2027
VT3989
25, 50, 100,150 or 200 mg capsules for oral administration.
Nivolumab & Ipilimumab
"Nivolumab infusion - 360 mg every 3 weeks, 30-minute intravenous infusion~Ipilimumab infusion - 1 mg/kg every 6 weeks, 30-minute intravenous infusion"
Osimertinib
40 or 80 mg tablets for oral administration
RECRUITING
Peter MacCullum Cancer Centre, Melbourne
RECRUITING
Monash Health, Clayton
RECRUITING
Linear Clinical Research, Nedlands
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
RECRUITING
Virginia Cancer Specialists, PC, Arlington
RECRUITING
M Health Fairview University of Minnesota Medical Center, Minneapolis
RECRUITING
University of Chicago Medical Center, Chicago
RECRUITING
MD Anderson Cancer Center, Houston
RECRUITING
NEXT Oncology, San Antonio
RECRUITING
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
RECRUITING
Massachusetts General Hospital, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
Vivace Therapeutics, Inc
INDUSTRY